Triazolopyrimidines and related analogs as HSP90-inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 31, 2006
Issued Date -
N/A
app pub date -
Sep 20, 2004
filing date -
Sep 18, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, diastereomer, pharmaceutically acceptable salt or prodrug thereof, ##STR00001## Wherein R.sup.1 is halogen, --OR.sup.11, --SR.sup.11 or lower alkyl; R.sup.2 is --NHR.sup.8; R.sup.4 is --CHR.sup.12--, --C(O)--, --C(S)--, --S(O)-- or --S.sub.2--; and R.sup.5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 3 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, and the heterocyclic group is substituted with 3 to 5 substituents.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully